Grifols (NASDAQ:GRFS) Sees Large Volume Increase – Here’s What Happened

Grifols, S.A. (NASDAQ:GRFS) saw unusually-high trading volume on Wednesday . Approximately 1,401,980 shares were traded during trading, an increase of 8% from the previous session’s volume of 1,298,023 shares.The stock last traded at $7.68 and had previously closed at $7.73.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Stock Performance

The stock has a market capitalization of $5.44 billion, a price-to-earnings ratio of 6.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm’s 50 day moving average is $7.49 and its 200-day moving average is $8.15.

Institutional Trading of Grifols

A number of institutional investors and hedge funds have recently made changes to their positions in GRFS. R Squared Ltd purchased a new stake in Grifols in the 4th quarter worth $28,000. GAMMA Investing LLC increased its stake in Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 6,335 shares in the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Grifols in the fourth quarter valued at approximately $75,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.